ORGO · Organogenesis Holdings Inc. · Webcasts, Transcripts & Audio
$1.27
-0.02 (-1.55%)
At close · Oct 6
Return incl. dividend (before tax)
Market Cap
$181.43M
Shares
128.67M
Volume · Oct 5
1.83M
Avg daily vol (3M)
768.83K
Organogenesis Holdings Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Organogenesis Holdings Inc. (ORGO), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲2.7%
$116.86M
$215,000
'22 Q3
22-11-09
▼9.7%
$115.52M
$7.49M
'22 Q4
23-03-01
▲10.8%
$107.64M
−$2.97M
'23 Q1
23-05-10
▼3.4%
$117.32M
$5.32M
'23 Q2
23-08-09
▼7.1%
$108.53M
$3.17M
'23 Q3
23-11-09
▼13.7%
$99.65M
−$569,000
'23 Q4
24-02-29
▲2.2%
$109.98M
−$2.10M
'24 Q1
24-05-09
▲11%
$130.23M
−$17.04M
'24 Q2
24-08-08
▲6.1%
$115.18M
$12.33M
'24 Q3
24-11-12
▲27.1%
$126.66M
$7.67M
'24 Q4
25-02-27
▼21.2%
$86.69M
−$18.84M
'25 Q1
25-05-08
▼22.4%
$101.00M
−$9.39M
'25 Q2
25-08-07
▲31%
$150.86M
$21.57M
'25 Q3
25-11-06
▲78.1%
$225.61M
$43.70M
'25 Q4
26-02-26
▼57.1%
$37.23M
−$53.16M
'26 Q1
26-05-07
LATEST
▼56.7%
$43.76M
−$96.27M
'26 Q2
26-08-06
Earnings call
FY26 · Q2
2026-08-06
Organogenesis Holdings Inc. (ORGO) Q2 2026 Earnings Call Transcript
Cautious tone
Revenue decline and guidance
CMS coverage and payment changes
Liquidity and financing
Revenue
$43.76M
▼ 56.7% YoY Diluted EPS
$-0.77
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Organogenesis Holdings Inc. (ORGO) Q1 2026 Earnings Call Transcript
Cautious tone
2026 guidance and outlook
Operational disruption (Wiser, MAC)
Renew BLA submission (knee osteoarthritis)
Revenue
$37.23M
▼ 57.1% YoY Diluted EPS
$-0.44
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Organogenesis Holdings Inc. (ORGO) Q4 2025 Earnings Call Transcript
Positive tone
CMS Policy and Reimbursement
Market Disruption and Clinician Confusion
RENEW Program / Knee Osteoarthritis
Revenue
$225.61M*
▲ 78.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Organogenesis Holdings Inc. (ORGO) Q3 2025 Earnings Call Transcript
Confident tone
ReNu Phase III program and BLA
Financial guidance and operating expenses
LCD coverage and competitive positioning
Revenue
$150.86M
▲ 31% YoY Diluted EPS
$0.11
▲ 22.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Organogenesis Holdings Inc. (ORGO) Q2 2025 Earnings Call Transcript
Positive tone
CMS Proposed LCD and Payment Reform
2025 Financial Guidance
ReNu (Knee OA) Program
Revenue
$101.00M
▼ 22.4% YoY Diluted EPS
$-0.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Organogenesis Holdings Inc. (ORGO) Q1 2025 Earnings Call Transcript
Positive tone
LCD Delay and CMS Coverage Policy
Full Portfolio and PuraPly AM Availability
RENEW Phase III Program and BLA Submission
Revenue
$86.69M
▼ 21.2% YoY Diluted EPS
$-0.17
Gross margin
72.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Organogenesis Holdings Inc. (ORGO) Q4 2024 Earnings Call Transcript
Positive tone
LCD implementation and CMS policy
2025 financial guidance
ReNu knee osteoarthritis program
Revenue
$126.66M*
▲ 27.1% YoY Gross margin
75.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Organogenesis Holdings Inc. (ORGO) Q3 2024 Earnings Call Transcript
Positive tone
RENEW Phase 3 clinical program / BLA submission
Avista Healthcare Partners financing
CMS payment policy and physician fee schedule
Revenue
$115.18M
▲ 6.1% YoY Diluted EPS
$0.09
▲ 350% YoY Gross margin
76.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Organogenesis Holdings Inc. (ORGO) Q2 2024 Earnings Call Transcript
Positive tone
Medicare reimbursement / MAC coverage (LCDs)
ReNu Phase III program and BLA pathway
Clinical evidence and real-world data
Revenue
$130.23M
▲ 11% YoY Diluted EPS
$-0.13
▼ 425% YoY Gross margin
77.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Organogenesis Holdings Inc. (ORGO) Q1 2024 Earnings Call Transcript
Confident tone
Medicare reimbursement and proposed LCD for skin substitutes
ReNu Phase III clinical trial for knee osteoarthritis
Regulatory path and FDA interaction for ReNu
Revenue
$109.98M
▲ 2.2% YoY Diluted EPS
$-0.02
Gross margin
73.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-29
Organogenesis Holdings Inc. (ORGO) Q4 2023 Earnings Call Transcript
Cautious tone
Q4 financial results
ReNu Phase III clinical trials
LCD disruption and recovery
Revenue
$99.65M*
▼ 13.7% YoY Gross margin
72.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Organogenesis Holdings Inc. (ORGO) Q3 2023 Earnings Call Transcript
Revenue
$108.53M
▼ 7.1% YoY Diluted EPS
$0.02
Gross margin
76.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Organogenesis Holdings Inc. (ORGO) Q2 2023 Earnings Call Transcript
Revenue
$117.32M
▼ 3.4% YoY Diluted EPS
$0.04
▼ 42.9% YoY Gross margin
77.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Organogenesis Holdings Inc. (ORGO) Q1 2023 Earnings Call Transcript
Revenue
$107.64M
▲ 10.8% YoY Diluted EPS
$-0.02
Gross margin
75.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-01
Organogenesis Holdings Inc. (ORGO) Q4 2022 Earnings Call Transcript
Revenue
$115.52M*
▼ 9.7% YoY Gross margin
76.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Organogenesis Holdings Inc. (ORGO) Q3 2022 Earnings Call Transcript
Revenue
$116.86M
▲ 2.7% YoY Diluted EPS
$0.00
▼ 100% YoY Gross margin
77.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Organogenesis Holdings Inc. (ORGO) Q2 2022 Earnings Call Transcript
Revenue
$121.40M
▼ 1.5% YoY Diluted EPS
$0.07
▼ 53.3% YoY Gross margin
78.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Organogenesis Holdings Inc. (ORGO) Q1 2022 Earnings Call Transcript
Revenue
$97.12M
▼ 5.3% YoY Diluted EPS
$-0.01
▼ 114.3% YoY Gross margin
74.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
Organogenesis Holdings Inc. (ORGO) Q4 2021 Earnings Call Transcript
Revenue
$127.86M*
▲ 19.7% YoY Gross margin
74.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Organogenesis Holdings Inc. (ORGO) Q3 2021 Earnings Call Transcript
Revenue
$113.75M
▲ 12.9% YoY Diluted EPS
$0.09
▼ 52.6% YoY Gross margin
77.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Organogenesis Holdings Inc. (ORGO) Q2 2021 Earnings Call Transcript
Revenue
$123.20M
▲ 78.6% YoY Diluted EPS
$0.15
Gross margin
75.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Organogenesis Holdings Inc. (ORGO) Q1 2021 Earnings Call Transcript
Revenue
$102.55M
▲ 66.1% YoY Diluted EPS
$0.07
Gross margin
75.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-16
Organogenesis Holdings Inc. (ORGO) Q4 2020 Earnings Call Transcript
Revenue
$106.81M*
▲ 43.1% YoY Gross margin
76.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-09
Organogenesis Holdings Inc. (ORGO) Q3 2020 Earnings Call Transcript
Revenue
$100.80M
▲ 56.8% YoY Diluted EPS
$0.19
Gross margin
77.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-20
Organogenesis Holdings Inc. (ORGO) Q2 2020 Earnings Call Transcript
Revenue
$68.96M
▲ 6.2% YoY Diluted EPS
$-0.05
Gross margin
70.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-08
Organogenesis Holdings Inc. (ORGO) Q1 2020 Earnings Call Transcript
Revenue
$61.73M
▲ 8.1% YoY Diluted EPS
$-0.16
Gross margin
69.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-09
Organogenesis Holdings Inc. (ORGO) Q4 2019 Earnings Call
Revenue
$74.64M*
▲ 17.4% YoY Gross margin
72.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–27 of 27 webcasts